Abstract
Fibronectin (FN) is a glykoprotein found in plasma [1, 2] and in cell-surface membranes [2]. It occurs in both soluble and insoluble forms. FN has been intensively studied because of its frequent interactions with cells and macromolecules. It may influence a number of physiological processes including phagocytosis [3, 4] remodeling during embryogenesis and wound healing [5]. The concentration of plasma FN is altered in certain disease states. Low FN levels have been seen in sepsis [6–9], burn injury [6, 7, 10], and acute lymphoblastic leukemia (ALL) in adults [11,12]. In our previous study [13], we noticed that the plasma FN level in patients with ALL prior to chemotherapy was significantly lower than during remission. A significant fall in plasma FN level was found in patients with viral or bacterial infections undergoing chemotherapy, and a subsequent increase in plasma FN level when the infection was treated successfully. Changes in FN concentration related to stage of disease, clinical condition, and subsequent complications as presented above have encouraged us to start clinical trials of this drug in substitutive treatment of patients with acute leukemia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Mosesson MW, Amrani DD (1980) The structure and biologic activities of plasma fibronectin. Blood 56: 145–158
Stenman S, Vaheri A (1978) Distribution of major connective tissue protein, fibronectin in normal human tissue. J Exp Med 147: 1054–1064
Gaudemand H (1983) La fibronectine plasmatique. Rev Fr Transfus Immunohematol 26 (3): 279–298
Saba TM, Blumenstock FA, Weber P, Kaplan JE (1978) Physiologic role of cold-insoluble globulin in systemic host defence: implications of its characterization as the opsonic a2-surface-binding glycoprotein. Ann NY Acad Sci 312–343
Clark RA, Lanigan JM, Delia Pelle P, Manseau E, Dvorak HF, Colvin R (1982) Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol 79: 264–269
Lanser MS, Saba TM (1983) Correction of serum opsonic defects after burn sepsis by fibronectin administration. Arch Surg 118: 338–341
Lanser MS, Saba TM, Scovill WA (1980) Opsonic glycoprotein/plasma fibronectin/levels after burn injury: relationship to extent of burn and development of sepsis. 192: 776–782
Mosher DF, Williams EM (1978) Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation. J Lab Clin Med 91: 729–735
Robbins AB, Deran JE, Reese AC, Mansberger AR (1981) Clinical response to coldinsoluble globulin replacement in a patient with sepsis and thermal injury. Ann J Surg 142: 636–638
Grossman JE, Demling RH, Duy ND, Mosher DF Response of plasma fibronectin to major body burn. J Trauma 20: 967–970
Choate JJ, Mosher DF (1983) Fibronectin concentration in plasma patients with breast cancer, colon cancer and acute leukemia. Cancer 51: 1142–1147
Boughton BJ, Simpson A (1982) Plasma fibronectin in acute leukemia. Br J Haematol 51: 487–491
Matysiak M, Hryniewicz HJ, Ochocka M (1987) Plasma fibronectin in children with acute leukemia and malignant lymphoma. Med Pediatr Oncol 15 (6): 333
Mancini G, Carbonara AO, Heremans JF (1965) Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235–240
Wahlin YB, Matsson L (1988) Oral mucosal lesions in patients with acute leukemia and related disorders during cytotoxic therapy. Scand J Dent Res 96: 128–136
Guggenheimer J, Verbin RS, Appel BN, Schmutz J (1977) Clinicopathologic effects of cancer chemotherapeutic agents on human buccal mucosa. Oral Surg 44: 58–63
Lockhart PB, Sonis ST (1981) Alternations in the oral mucosa caused by chemotherapeutic agents. A histologic study. J Dermatol Surg Oncol 7: 1019–1025
Lynch MA, Ship II (1967) Initial oral manifestations of leukemia. J Am Dent Assoc 75: 932 - 940
Sonis A, Sonis S (1979) Oral complications of cancer chemotherapy in pediatric patients. J Pedod 3: 122–128
Bruhn HD, Heimburger N (1976) Factor Vlll-related antigen and cold-insoluble globulin in leukemias and carcinomas. Haemostasis 5: 189–192
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Matysiak, M., Ochocka, M., Klos, M. (1990). Fibronectin in Stomatitis Therapy of Leukemic Children. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_108
Download citation
DOI: https://doi.org/10.1007/978-3-642-74643-7_108
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50984-4
Online ISBN: 978-3-642-74643-7
eBook Packages: Springer Book Archive